At @EHA_Hematology, we’ll be showcasing our clinical advancements across multiple blood cancers and connecting with the global community. https://t.co/u1xNRYNPrO
At #EULAR2026, conversations on the ground are focused on how to achieve and maintain disease control in #PsA and #axSpA. AbbVie is on-site, sharing new research and a commitment to improving patient outcomes. Learn more: https://t.co/H2rNBLvGuV
[Animation description: Diverse profile illustrations transition to on-screen text highlighting AbbVie's 26 accepted abstracts across five rheumatic diseases at EULAR 2026, closing with a 'See you there!' message.]
At #EULAR2026, we're presenting abstracts across our #rheumatology portfolio. We remain committed to building on our deep expertise and historic legacy in immunology research. Explore what drives us in immunology: https://t.co/H2rNBLvGuV
#DYK migraine is a prevalent and debilitating neurological disease, impacting roughly 14% of the global population, with a higher incidence in women than men?
Learn more about a new indication for the acute treatment of migraine: https://t.co/FSnJbbMRL2
At #ASCO26, we're inviting #HCPs to stop by our booth and share their unique connection to the #oncology community – showing how each connection strengthens our commitment to science for this community. Join us at Booth 27093.
The @EU_Commission has granted AbbVie approval of our medicine as part of a combination regimen for previously untreated patients with chronic lymphocytic leukemia (#CLL). https://t.co/hXy1xSvBh1
[Video description: On-screen text reads, "AbbVie data at ASCO 2026. AbbVie will share new data across: Small cell lung cancer, Ovarian cancer, Head and neck cancer, Prostate cancer, Multiple myeloma."]
At this year's @ASCO Annual Meeting, our team will share new data across solid tumors and blood cancers from our novel platforms. Read more: https://t.co/45tL2BDVSS #ASCO26
Next week we’ll be at #ASCP2026 presenting our latest data in psychiatric disorder research. Stop by our posters to see how our findings are supporting progress for people living with mental health conditions.
...understanding of IBD and helping raise the standard of care through scientific innovation and a broad portfolio of marketed and investigational therapies.”]
At #DDW2026, AbbVie is sharing new long-term #IBD data, including real-world evidence and clinical results reinforcing treatment efficacy, safety profiles, and durability across Crohn's Disease and Ulcerative Colitis. Learn more: https://t.co/yM0rZ6XnTw
[Video description: Quote from Andrew Anisfeld, Ph.D., Vice President, Global Medical Affairs, Immunology, AbbVie. On-screen text reads, “As a leader in gastroenterology, AbbVie remains focused on advancing the...